#United States #New York #Actinium Pharmaceuticals #H.C. Wainwright #targeted radiotherapies

Actinium Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

Actinium Pharmaceuticals, Inc., listed on NYSE American under the ticker ATNM, has taken a significant step towards showcasing its advancements in oncology treatment. The company recently announced that Sandesh Seth, the Chairman and CEO, will represent Actinium at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled from September 14 to 16, 2026, in New York City.

Key Highlights of the Conference

At this esteemed event, which attracts investors and thought leaders from across the globe, Mr. Seth will deliver a presentation on September 14, 2026, between 3:00 p.m. and 3:30 p.m. ET. In addition to the formal presentation, attendees will have the opportunity to engage directly with the company’s management during scheduled one-on-one meetings. This setup not only provides vital insights into the company’s strategic direction and growth potential but also allows investors to ask tailored questions about Actinium's innovative therapies.

Actinium's Mission and Innovations

Actinium Pharmaceuticals stands out as a trailblazer in the realm of targeted radiotherapies, with a firm commitment to improving cancer treatment outcomes. The company’s strategy revolves around developing cutting-edge radiopharmaceuticals aimed at both solid tumors and hematologic malignancies. Their mission focuses on enhancing the therapeutic efficacy of treatments while reducing toxicity to healthy tissue. This approach combines in-depth expertise in tumor biology, translational medicine, and radiochemistry, positioning Actinium at the forefront of cancer therapy advancement.

Notably, Actinium's pipeline boasts promising candidates such as:
1. ATNM-400: Aimed at treating metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer, ATNM-400 targets a novel antigen distinct from traditional options like PSMA.
2. Actimab-A: Recognized as a significant therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), Actimab-A is undergoing development alongside the National Cancer Institute (NCI). It has already demonstrated improved survival rates in relapsed and refractory AML patients.
3. Iomab-B and Iomab-ACT: These are targeted conditioning agents designed for use in bone marrow transplants and gene therapy conditioning, further diversifying Actinium's portfolio of innovative cancer therapies.

With an impressive intellectual property portfolio of around 250 patents, Actinium continues to seek advancements in the production of Ac-225, which plays a crucial role in its therapeutic strategies. Their relentless pursuit of innovation illustrates their commitment to transforming how cancer is treated.

The Significance of the Global Investment Conference

Participation in the H.C. Wainwright conference marks a vital opportunity for Actinium to connect with potential investors and industry experts, ensuring that the company remains a pivotal player in the pharmaceutical landscape. As Actinium shares its insights and leads discussions on future growth prospects, the event is set to highlight both the urgent need for effective cancer treatments and the innovative solutions Actinium is developing.

As the date of the conference approaches, interest in Actinium's groundbreaking work in targeted radiotherapies will undoubtedly grow, reflecting a broader commitment within the medical community to address the challenges posed by cancer diagnoses. Stakeholders across the board will be keenly watching for developments from the event as they hold significant implications for the future of cancer care and treatment strategies.

For further information about Actinium Pharmaceuticals and its pipeline, visit Actinium's official website.